The history of Sildenafil presents a complex picture for shareholders. While the initial release generated substantial returns, the expiration of its exclusive rights opened the avenue to cheaper versions, dramatically reducing revenue. This creates a specific dilemma for drug manufacturers relying on related blockbuster medications, suggesting tha

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. Initially a blockbuster drug, generating billions in sales , its exclusivity period created a deluge of generic competition , significantly diminishing its position . While some firms may seek to capitalize on similar conditions , the existing